Skip to main content

21 Result(s)

within L J Burns Remove this filter

previous disabled Page of 2
and

  1. No Access

    Article

    Metabolic syndrome and cardiovascular disease following hematopoietic cell transplantation: screening and preventive practice recommendations from CIBMTR and EBMT

    Metabolic syndrome (MetS) is a constellation of cardiovascular risk factors that increases the risk of cardiovascular disease, diabetes mellitus and all cause mortality. Long-term survivors of hematopoietic ce...

    Z DeFilipp, R F Duarte, J A Snowden, N S Majhail… in Bone Marrow Transplantation (2017)

  2. No Access

    Article

    Alternative donors extend transplantation for patients with lymphoma who lack an HLA matched donor

    Alternative donor transplantation is increasingly used for high-risk lymphoma patients. We analyzed 1593 transplant recipients (2000–2010) and compared transplant outcomes in recipients of 8/8 allele HLA-A, -B...

    V Bachanova, L J Burns, T Wang, J Carreras, R P Gale… in Bone Marrow Transplantation (2015)

  3. No Access

    Article

    Nasal GVHD

    N Randall, H Boyer, P J Martin, D Weisdorf, L J Burns… in Bone Marrow Transplantation (2015)

  4. No Access

    Article

    Pretransplantation fluorine-18-deoxyglucose-positron emission tomography scan has no influence on relapse and survival in non-Hodgkin lymphoma patients undergoing allo-SCT

    V Bachanova, Q Cao, C Ustun, A T K Kendi, J Froelich… in Bone Marrow Transplantation (2015)

  5. No Access

    Article

    Physician perceptions and practice patterns regarding fertility preservation in hematopoietic cell transplant recipients

    Physician practice variation may be a barrier to informing hematopoietic cell transplant (HCT) recipients about fertility preservation (FP) options. We surveyed HCT physicians in the United States to evaluate ...

    A W Loren, R Brazauskas, E J Chow, M Gilleece, J Halter… in Bone Marrow Transplantation (2013)

  6. No Access

    Article

    Hematopoietic cell transplantation for Waldenström macroglobulinemia

    Waldenström macroglobulinemia (WM) is a distinct indolent B-cell lymphoproliferative malignancy characterized by IgM paraproteinemia. Although the disease is sensitive to chemo-immunotherapy, it remains incura...

    V Bachanova, L J Burns in Bone Marrow Transplantation (2012)

  7. No Access

    Article

    Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation

    Advances in hematopoietic cell transplantation (HCT) technology and supportive care techniques have led to improvements in long-term survival after HCT. Emerging indications for transplantation, introduction o...

    N S Majhail, J D Rizzo, S J Lee, M Aljurf, Y Atsuta… in Bone Marrow Transplantation (2012)

  8. No Access

    Article

    Vitamin D status among long-term survivors of hematopoietic cell transplantation

    Little is known about serum vitamin D levels following hematopoietic cell transplantation (HCT). Patients are instructed to avoid sun exposure because of an increased risk of skin cancers. Altered gastrointest...

    K Robien, L G Strayer, N Majhail, D Lazovich, K S Baker… in Bone Marrow Transplantation (2011)

  9. No Access

    Article

    Screening, prevention and management of osteoporosis and bone loss in adult and pediatric hematopoietic cell transplant recipients

    Long-term survivors of hematopoietic cell transplantation (HCT) are at risk for loss of bone mineral density (BMD) and subsequent osteoporosis. There is a lack of clear guidelines for the screening, prevention...

    B L McClune, L E Polgreen, L A Burmeister, A H Blaes… in Bone Marrow Transplantation (2011)

  10. No Access

    Article

    Similar risks for hypothyroidism after allogeneic hematopoietic cell transplantation using TBI-based myeloablative and reduced-intensity conditioning regimens

    The risk of hypothyroidism after reduced-intensity hematopoietic cell transplantation (HCT) is not well known. We studied the incidence of hypothyroidism among a cohort of HCT recipients who had survived for ⩾...

    A Al-Hazzouri, Q Cao, L J Burns, D J Weisdorf, N S Majhail in Bone Marrow Transplantation (2009)

  11. No Access

    Article

    Fewer infections and lower infection-related mortality following non-myeloablative versus myeloablative conditioning for allotransplantation of patients with lymphoma

    Non-myeloablative (NMA) allogeneic donor SCT for patients with relapsed lymphoma is associated with lower treatment-related mortality (TRM). However, the impact of conditioning intensity on post transplant inf...

    V Bachanova, C G Brunstein, L J Burns, J S Miller, X Luo… in Bone Marrow Transplantation (2009)

  12. No Access

    Article

    High prevalence of metabolic syndrome after allogeneic hematopoietic cell transplantation

    We conducted a cross-sectional study to estimate the prevalence of metabolic syndrome, a clustering of risk factors associated with cardiovascular disease, among 86 adults who had allogeneic hematopoietic-cell...

    N S Majhail, M E Flowers, K K Ness, M Jagasia, P A Carpenter… in Bone Marrow Transplantation (2009)

  13. No Access

    Article

    New classification of chronic GVHD: added clarity from the consensus diagnoses

    The Diagnosis and Staging Working Group of the NIH Consensus Development Project on Criteria for Clinical Trials in chronic GVHD (CGVHD) recently proposed criteria for diagnosis and assessment of overall CGVHD...

    M Arora, S Nagaraj, J Witte, T E DeFor, M MacMillan… in Bone Marrow Transplantation (2009)

  14. No Access

    Article

    Iron overload in hematopoietic cell transplantation

    Iron overload, primarily related to RBC transfusions, is a relatively common complication in hematopoietic cell transplant (HCT) recipients. Iron overload increases the risk of infections, veno-occlusive disea...

    N S Majhail, H M Lazarus, L J Burns in Bone Marrow Transplantation (2008)

  15. No Access

    Article

    Pulmonary veno-occlusive disease following hematopoietic stem cell transplantation: a rare model of endothelial dysfunction

    Veno-occlusive disease is among the most serious complications following hematopoietic stem cell transplantation. While hepatic veno-occlusive disease occurs more commonly, the pulmonary variant remains quite ...

    M C Bunte, M M Patnaik, M R Pritzker, L J Burns in Bone Marrow Transplantation (2008)

  16. No Access

    Article

    Difficult stem cell mobilization despite adequate CD34+ cell dose predicts shortened progression free and overall survival after autologous HSCT for lymphoma

    Hematopoietic growth factors alone or in combination with myelosuppressive chemotherapy are used to mobilize peripheral blood stem cells for autologous transplantation. To identify characteristics of successfu...

    M Tomblyn, L J Burns, B Blazar, J Wagner, C Lee, T Rogers… in Bone Marrow Transplantation (2007)

  17. No Access

    Article

    Fludarabine vs cladribine plus busulfan and low-dose TBI as reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation: a prospective randomized trial

    Purine analogs are often used for conditioning preceding allogeneic hematopoietic stem cell transplantation (HCT). We prospectively tested fludarabine (Flu) 40 mg/m2/day × 5 days vs cladribine (Clad) 10 mg/m2/day...

    M Markova, J N Barker, J S Miller, M Arora, J E Wagner… in Bone Marrow Transplantation (2007)

  18. No Access

    Article

    Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, Center for International Blood and Marrow Transplant Research, and the American Society for Blood and Marrow Transplantation (EBMT/CIBMTR/ASBMT)

    More than 40 000 hematopoietic cell transplants (HCTs) are performed worldwide each year. With improvements in transplant technology, larger numbers of transplant recipients survive free of the disease for whi...

    J D Rizzo, J R Wingard, A Tichelli, S J Lee, M T Van Lint… in Bone Marrow Transplantation (2006)

  19. No Access

    Article

    Results of autologous and allogeneic hematopoietic cell transplant therapy for multiple myeloma

    We compared the results of autologous and allogeneic peripheral blood hematopoietic cell transplant (HCT) in 87 patients with multiple myeloma using myeloablative preparative regimen. Autologous transplant (n=70)...

    M Arora, P B McGlave, L J Burns, J S Miller, J N Barke… in Bone Marrow Transplantation (2005)

  20. No Access

    Article

    IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial

    We determined the safety, immune activating effects, and potential efficacy of i.v. infusion of ex vivo interleukin-2 (IL-2) activated natural killer (NK) cells (part I) or IL-2 boluses (part II) during daily s.c...

    L J Burns, D J Weisdorf, T E DeFor, D H Vesole, T L Repka… in Bone Marrow Transplantation (2003)

previous disabled Page of 2